The group operates through its subsidiaries whose principle activities include discovering and developing drug therapies.The group’s NF-specific drug evaluation platform include transgenic mouse models, cell and tissue based xenograft models, a tumor bank, biomarkers, tumor explant models, cell based assays and other enzymatic screens. The group operates from United States.
